Correlation Engine 2.0
Clear Search sequence regions


filter terms:
No tags found.

No abstract available.

Citation

Schaper-Gerhardt K, Gutzmer R, Angela Y, Zimmer L, Livingstone E, Schadendorf D, Hassel JC, Weishaupt C, Remes B, Kubat L, Spassova I, Becker JC. The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations. European journal of cancer (Oxford, England : 1990). 2024 May;202:113984


PMID: 0

View Full Text